- Home
- IKNA vs OSTX Comparison
IKNA vs OSTX Comparison
Compare IKNA & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- OSTX
- Stock Information
- Founded
- IKNA 2016
- OSTX 2018
- Country
- IKNA United States
- OSTX United States
- Employees
- IKNA N/A
- OSTX N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- OSTX
- Sector
- IKNA Health Care
- OSTX
- Exchange
- IKNA Nasdaq
- OSTX NYSE
- Market Cap
- IKNA 80.8M
- OSTX 86.5M
- IPO Year
- IKNA 2021
- OSTX 2024
- Fundamental
- Price
- IKNA $1.71
- OSTX $1.95
- Analyst Decision
- IKNA Buy
- OSTX Strong Buy
- Analyst Count
- IKNA 2
- OSTX 1
- Target Price
- IKNA $3.00
- OSTX $21.00
- AVG Volume (30 Days)
- IKNA 60.6K
- OSTX 25.8K
- Earning Date
- IKNA 11-07-2024
- OSTX 11-15-2024
- Dividend Yield
- IKNA N/A
- OSTX N/A
- EPS Growth
- IKNA N/A
- OSTX N/A
- EPS
- IKNA N/A
- OSTX N/A
- Revenue
- IKNA $659,000.00
- OSTX N/A
- Revenue This Year
- IKNA N/A
- OSTX N/A
- Revenue Next Year
- IKNA N/A
- OSTX $9,900.00
- P/E Ratio
- IKNA N/A
- OSTX N/A
- Revenue Growth
- IKNA N/A
- OSTX N/A
- 52 Week Low
- IKNA $1.22
- OSTX $1.58
- 52 Week High
- IKNA $2.32
- OSTX $4.90
- Technical
- Relative Strength Index (RSI)
- IKNA 49.85
- OSTX N/A
- Support Level
- IKNA $1.71
- OSTX N/A
- Resistance Level
- IKNA $1.77
- OSTX N/A
- Average True Range (ATR)
- IKNA 0.05
- OSTX 0.00
- MACD
- IKNA -0.00
- OSTX 0.00
- Stochastic Oscillator
- IKNA 38.46
- OSTX 0.00
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.